This book is the result of thousands of encounters with tube-fed infants and their families over the past four decades. The ailing and fragile children, suffering from a myriad of medical conditions acted as muses and mentors teaching more than could be expected. This book is addressed to medical professionals, early interventionists, pediatricians, child surgeons, nurses, dieticians, occupational therapists, speech and language pathologists (SLPs), feeding specialists, psychologists, physiotherapists, infant psychiatrists as well as parents. The medically fragile child (MFC) is the subject of the authors’ work when it is concerned with enteral nutrition support (ENS) by means of a feeding tube (ENT). As pediatricians and psychotherapists, they have been treating eating and feeding disorders of children since 1986 and with this book they pass on knowledge they have garnered over three decades. Over 5,000 children have been weaned off their feeding tubes. Tube weaning requires the evaluation of medical, nutritional, sensory, developmental, metabolic and growth-related findings. The review of the literature around this subject has provided a source of inspiration as well as critical self-reflection; the authors wish to offer their insight and ideas on how to approach child-led tube-management and tube-weaning to all healthcare professional involved in the management of these children.
With an emphasis on the fundamental and practical aspects of ADME for therapeutic proteins, this book helps readers strategize, plan and implement translational research for biologic drugs. • Details cutting-edge ADME (absorption, distribution, metabolism and excretion) and PKPD (pharmacokinetic / pharmacodynamics) modeling for biologic drugs • Combines theoretical with practical aspects of ADME in biologic drug discovery and development and compares innovator biologics with biosimilar biologics and small molecules with biologics, giving a lessons-learned perspective • Includes case studies about leveraging ADME to improve biologics drug development for monoclonal antibodies, fusion proteins, pegylated proteins, ADCs, bispecifics, and vaccines • Presents regulatory expectations and industry perspectives for developing biologic drugs in USA, EU, and Japan • Provides mechanistic insight into biodistribution and target-driven pharmacokinetics in important sites of action such as tumors and the brain
Lists records and statistics related to human beings, animals, science, technology, buildings, transportation, business, arts, entertainment, human achievement, and sports
Thank you for visiting our website. Would you like to provide feedback on how we could improve your experience?
This site does not use any third party cookies with one exception — it uses cookies from Google to deliver its services and to analyze traffic.Learn More.